Suppr超能文献

转化生长因子-β1诱导的miR-202通过抑制人骨肉瘤细胞凋亡介导耐药性。

TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.

作者信息

Lin Zaijun, Song Dianwen, Wei Haifeng, Yang Xinghai, Liu Tielong, Yan Wangjun, Xiao Jianru

机构信息

Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China.

出版信息

J Cancer Res Clin Oncol. 2016 Jan;142(1):239-46. doi: 10.1007/s00432-015-2028-9. Epub 2015 Aug 15.

Abstract

PURPOSE

A number of studies have demonstrated that microRNAs play a critical role in osteosarcoma progression, therapy and drug resistance. MicroRNA-202 has proven to be dysregulated in many human cancer studies. This study aimed to explore miR-202 contributions to drug resistance in osteosarcoma.

METHODS

miR-202 expression was measured by real-time PCR in patient tissues, cell lines or cells treated with TGF-β1, using siRNA to knock down the expression of Smad2, Smad3 and Smad4. miR-202 mimics, inhibitor and scramble siRNA were transfected into osteosarcoma cells to observe effects on cell apoptosis and drug resistance. Moreover, relationships of miR-202 level with PDCD4 were investigated by luciferase reporter assay, real-time PCR and Western blotting.

RESULTS

We found that miR-202 is overexpressed in osteosarcoma tissues when compared with normal human osteoblasts and TGF-β1 can induce the expression of miR-202. Transfection of miR-202 mimics into osteosarcoma cell lines significantly promotes chemotherapy resistance by targeting PDCD4, a tumor suppressor which is involved in apoptosis. In contrast, transfection of miR-202 inhibitor enhances the drug sensitivity and apoptosis.

CONCLUSIONS

This study provides new insights into miRNA-202 in osteosarcoma as a potential molecular target for chemotherapy.

摘要

目的

多项研究表明,微小RNA在骨肉瘤进展、治疗及耐药性中起关键作用。在许多人类癌症研究中,已证实微小RNA-202表达失调。本研究旨在探讨miR-202在骨肉瘤耐药性中的作用。

方法

采用实时定量PCR检测患者组织、细胞系或经转化生长因子-β1(TGF-β1)处理的细胞中miR-202的表达,使用小干扰RNA(siRNA)敲低Smad2、Smad3和Smad4的表达。将miR-202模拟物、抑制剂及乱序siRNA转染至骨肉瘤细胞,观察其对细胞凋亡和耐药性的影响。此外,通过荧光素酶报告基因检测、实时定量PCR及蛋白质免疫印迹法研究miR-202水平与程序性细胞死亡蛋白4(PDCD4)的关系。

结果

我们发现,与正常人成骨细胞相比,miR-202在骨肉瘤组织中过表达,且TGF-β1可诱导miR-202表达。将miR-202模拟物转染至骨肉瘤细胞系,通过靶向参与细胞凋亡的肿瘤抑制因子PDCD4,显著促进化疗耐药性。相反,转染miR-202抑制剂可增强药物敏感性并促进细胞凋亡。

结论

本研究为miR-202作为骨肉瘤化疗潜在分子靶点提供了新见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验